Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: oakervee he. Toxicol Rep. 2019 Apr 19;6:369-379. doi: 10.1016/j.toxrep.2019.04.006. eCollection 2019. Toxicol Rep. 2019. PMID: 31080744 Free PMC article.
Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Tornatore L, Capece D, D'Andrea D, Begalli F, Verzella D, Bennett J, Acton G, Campbell EA, Kelly J, Tarbit M, Adams N, Bannoo S, Leonardi A, Sandomenico A, Raimondo D, Ruvo M, Chambery A, Oblak M, Al-Obaidi MJ, Kaczmarski RS, Gabriel I, Oakervee HE, Kaiser MF, Wechalekar A, Benjamin R, Apperley JF, Auner HW, Franzoso G. Tornatore L, et al. Among authors: oakervee he. Br J Haematol. 2019 May;185(3):588-592. doi: 10.1111/bjh.15569. Epub 2018 Sep 26. Br J Haematol. 2019. PMID: 30255568 Free article. No abstract available.
Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.
Dignan FL, Greenblatt D, Cox M, Cavenagh J, Oakervee H, Apperley JF, Fielding AK, Pagliuca A, Mufti G, Raj K, Marks DI, Amrolia P, Peniket A, Medd P, Potter MN, Shaw BE, Scarisbrick JJ. Dignan FL, et al. Bone Marrow Transplant. 2012 Jun;47(6):824-30. doi: 10.1038/bmt.2011.186. Epub 2011 Sep 19. Bone Marrow Transplant. 2012. PMID: 21927038 Clinical Trial.
Thalidomide in multiple myeloma: current status and future prospects.
Cavenagh JD, Oakervee H; UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces. Cavenagh JD, et al. Br J Haematol. 2003 Jan;120(1):18-26. doi: 10.1046/j.1365-2141.2003.03902.x. Br J Haematol. 2003. PMID: 12492572 Free article. No abstract available.
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.
Jurgensen-Rauch A, Gibbs S, Farrell M, Aries J, Grantham M, Eccersley L, Gribben J, Hallam S, Oakervee H, Cavenagh J, Davies J, Sive J. Jurgensen-Rauch A, et al. Br J Haematol. 2021 Apr;193(2):420-423. doi: 10.1111/bjh.17379. Epub 2021 Mar 13. Br J Haematol. 2021. PMID: 33713421 No abstract available.
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network. Popat R, et al. Br J Haematol. 2019 May;185(3):573-578. doi: 10.1111/bjh.15551. Epub 2018 Aug 20. Br J Haematol. 2019. PMID: 30125960 Free article. Clinical Trial. No abstract available.
52 results